Results 101 to 110 of about 4,584 (134)

Broadly neutralizing antibody-secreting CAR-T cells elicit Fc-mediated effector functions <i>in vitro</i> and suppress HIV in humanized mice. [PDF]

Front Immunol
Stylianidou Z, Gerlo S, Wejda M, Burg E, De Smet E, Noppe Y, Verschoore M, Van Cleemput J, Vandekerckhove L, Witkowski W.   +9 more
europepmc   +1 more source

The Evolving Role of Bispecific Antibodies in Oncogene-Driven NSCLC. [PDF]

Cancers (Basel)
Wang JC, Rosas D, Raez LE.
europepmc   +1 more source

A tri-specific EGFR/cMet/VEGF antibody demonstrates potent multi-mechanistic activity in preclinical triple-negative breast cancer models. [PDF]

J Biol Chem
Pu P, Jin Y, Zhang S, Xu Y, Chen P, Zhou F, Sun P, Jiang H, Huang S, Chen L, Fu M, Zha Z, MacWilliams MP, Chiu ML.   +13 more
europepmc   +1 more source

Evidence for the use of anti-CD20 therapeutic antibodies in immune thrombotic thrombocytopenic purpura management: a review. [PDF]

Front Pharmacol
Halkidis K, Meng C, Snyder J.
europepmc   +1 more source

Encephalitic alphavirus infection induces long-term humoral and cell-mediated responses in seropositive participants from Panama. [PDF]

PLoS Negl Trop Dis
Cohen CA, Carrera JP, Galué J, Beltran D, Corrales R, Rivera LF, Chaverra Z, Suarez Y, Marciaga J, Rock ML, Ha MC, Wetzel DL, O'Brien EV, Abelson D, Bornholdt ZA, Moyer CL, Zeitlin L, Pascale JM, Dye JM, López-Vergés S, Herbert AS.   +20 more
europepmc   +1 more source

Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms. [PDF]

J Inflamm Res
Maglio A, Vitale C, D'Auria LO, Longobardi V, Franzese A, Pelaia C, Pelaia G, Calabrese C, Vatrella A.   +8 more
europepmc   +1 more source

Multivalent Antibody-Recruiting Molecules for Targeted Immune-Killing of Carbonic Anhydrase IX-Expressing Cancer Cells. [PDF]

Angew Chem Int Ed Engl
Peng H, De Baere J, Cappellesso F, English K, Deswarte K, Laoui D, Lambrecht BN, De Geest BG, Louage B.   +8 more
europepmc   +1 more source

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL. [PDF]

Hemasphere
Pinkle D, Cornils M, Dietterle A, Laqua A, Kurschies M, Heymann J, Funke E, Fanter P, Gupta DD, Reimer C, Mahachi DT, Gehlert CL, Winterberg D, Vossen-Gajcy M, Müller X, Balow G, Iben K, Barz M, Bastian L, Baldus C, Kowol M, Kikvadze S, Wurm AA, Logvinova E, Vokuhl C, Schmid JP, Jeremias I, Klausz K, Peipp M, Schrappe M, Baccelli I, Poirier N, Brüggemann M, Cario G, Schewe DM, Lenk L.   +35 more
europepmc   +1 more source

Humoral immunity in cancer. [PDF]

Signal Transduct Target Ther
Leonard J, Duhamel M, Salzet M.
europepmc   +1 more source